한글목차

세계 콜레라 백신 시장은 2024년 9,732만 달러로 평가되었고, 예측 기간 동안 9.32%의 연평균 복합 성장률(CAGR)로 2030년에는 1억 6,650만 달러에 달할 것으로 예상됩니다.

세계 콜레라 백신 시장은 여러 요인에 의해 주도되고 있으며, 특히 위생 상태가 열악하고 깨끗한 물에 대한 접근성이 제한적인 지역에서 콜레라 발생 빈도가 증가하고 있습니다. 기후 변화와 홍수와 같은 자연재해, 진행 중인 분쟁은 콜레라 질병의 확산을 더욱 부추기고 있습니다. 효능이 향상되고, 예방 효과가 오래 지속되며, 단회 접종 요법과 같은 간편한 투여 방법을 갖춘 보다 효과적인 백신의 개발은 시장 수요를 촉진하고 있습니다. 백신 접종 프로그램에 자금을 지원하는 정부 및 국제기구의 지원은 전 세계 콜레라 퇴치 노력을 가속화하는 데 도움이 되고 있습니다. 전 세계적으로 여행으로 인한 인구 이동이 증가함에 따라 질병 전파의 위험이 높아져 콜레라 발생을 예방하기 위한 백신 접종의 필요성이 더욱 커지고 있습니다.

시장 성장 촉진요인

콜레라 발생 빈도 증가

주요 시장 이슈

물류 및 공급망 장벽

주요 시장 동향

세계 여행과 이동 증가

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 콜레라 백신 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 유형별(Whole cell V. Cholerae O1 Recombinant With B-Subunit, Killed Oral O1 & O139)
  • 제품별(Vaxchora, Dukoral, Shanchol, 기타)
  • 유통 채널별(병원 약국, 소매 약국, 기타)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 북미의 콜레라 백신 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 캐나다
  • 멕시코

제7장 유럽의 콜레라 백신 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 영국
  • 이탈리아
  • 프랑스
  • 스페인

제8장 아시아태평양의 콜레라 백신 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 인도
  • 일본
  • 한국
  • 호주

제9장 남미의 콜레라 백신 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 콜레라 백신 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 사우디아라비아
  • 아랍에미리트(UAE)

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 인수합병(M&A)(있는 경우)
• 제품 발매(있는 경우)
• 최근 동향

제13장 Porter의 Five Forces 분석

• 업계내 경쟁
• 신규 참여 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제14장 경쟁 구도

• Valneva SE
• Sanofi S.A.
• Emergent BioSolutions Inc.
• EuBiologics Co., Ltd.
• Shantha Biotechnics Limited
• Hilleman Laboratories Singapore Pte Ltd
• Astellas Pharma Inc.
• Incepta Pharmaceuticals Ltd.
• Bharat Biotech Ltd.
• Takeda Pharmaceutical Company Limited

제15장 전략적 제안

제16장 리서치사에 대해 & 면책사항

영문목차

Global Cholera Vaccines Market was valued at USD 97.32 Million in 2024 and is expected to reach USD 166.50 Million by 2030 with a CAGR of 9.32% during the forecast period. The global cholera vaccine market is driven by several factors, including the rising frequency of cholera outbreaks, especially in regions with poor sanitation and limited access to clean water. Climate change and natural disasters, such as floods, as well as ongoing conflicts, further contribute to the spread of the disease. The development of more effective vaccines, with improved efficacy, longer-lasting protection, and convenient administration methods like single-dose regimens, has boosted market demand. The support of governments and international organizations funding vaccination programs helps accelerate efforts to combat cholera globally. The increased movement of people due to global travel also raises the risk of disease transmission, further driving the need for cholera vaccination to prevent outbreaks.

Key Market Drivers

Rising Frequency of Cholera Outbreaks

The increasing frequency of cholera outbreaks, particularly in regions with poor sanitation and inadequate healthcare infrastructure, is one of the primary factors driving the global cholera vaccine market. Cholera, a highly contagious waterborne disease caused by the Vibrio cholerae bacterium, spreads rapidly in environments where access to clean water is limited, and waste disposal practices are inadequate. Countries with low-income economies, especially those in Sub-Saharan Africa, parts of South Asia, and the Middle East, are seeing frequent cholera outbreaks that put populations at high risk. The World Health Organization (WHO) has released global cholera statistics for 2023, revealing an alarming rise in both cases and deaths. Reported cholera cases increased by 13%, while deaths surged by 71% compared to 2022. Over 4,000 people lost their lives to a disease that is preventable and easily treatable. A total of 45 countries reported cases in 2023, up from 44 the previous year and 35 in 2021. Notably, 38% of the reported cases were among children under five years of age. Cholera, an acute intestinal infection, spreads through contaminated food and water, with communities lacking proper sanitation being the most affected.

Key Market Challenges

Logistical and Supply Chain Barriers

One of the significant challenges to cholera vaccination campaigns is the logistical complexity of vaccine distribution. Many cholera-endemic regions are remote, with limited access to transportation infrastructure, making it difficult to distribute vaccines efficiently. Vaccines often require specific storage conditions, such as refrigeration, which may not be feasible in low-resource settings with inadequate cold chain infrastructure. Political instability, conflicts, and natural disasters can disrupt supply chains and delay vaccination efforts. In regions where cholera outbreaks occur in areas with poor infrastructure, vaccines may not reach the target populations in time to prevent widespread infection. The logistical challenges associated with transporting and storing vaccines in such conditions can limit the effectiveness of vaccination campaigns and prevent the full potential of cholera vaccination from being realized.

Key Market Trends

Increased Global Travel and Mobility

As global travel continues to increase, the risk of infectious diseases, including cholera, spreading across borders has grown. International travel and migration expose individuals to areas with active cholera outbreaks, raising the risk of the disease being transmitted across regions and even continents. Countries with high volumes of international travelers, such as those in Europe, the United States, and the Middle East, are increasingly emphasizing the importance of cholera vaccination to protect travelers and prevent the global spread of the disease. Governments and health authorities have recognized the need for pre-travel vaccinations, particularly for those visiting endemic regions, as a measure to reduce the likelihood of outbreaks in non-endemic areas. In August 2024, Bharat Biotech announced the launch of its new oral cholera vaccine, Hillchol, following successful results from phase 3 trials. Developed under a license from Singapore's Hilleman Laboratories, Bharat Biotech will produce the vaccine with an annual capacity of 200 million doses.

Key Market Players

• Valneva SE
• Sanofi S.A.
• Emergent BioSolutions Inc.
• EuBiologics Co., Ltd.
• Shantha Biotechnics Limited
• Hilleman Laboratories Singapore Pte Ltd
• Astellas Pharma Inc.
• Incepta Pharmaceuticals Ltd.
• Bharat Biotech Ltd.
• Takeda Pharmaceutical Company Limited

Report Scope:

In this report, the Global Cholera Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cholera Vaccines Market, By Type:

• Whole cell V. Cholerae O1 Recombinant With B-Subunit
• Killed Oral O1 & O139

Cholera Vaccines Market, By Product:

• Vaxchora
• Dukoral
• Shanchol
• Others

Cholera Vaccines Market, By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Others

Cholera Vaccines Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cholera Vaccines Market.

Available Customizations:

Global Cholera Vaccines market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cholera Vaccines Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Whole cell V. Cholerae O1 Recombinant With B-Subunit and Killed Oral O1 & O139)
  • 5.2.2. By Product (Vaxchora, Dukoral, Shanchol, and Others)
  • 5.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Cholera Vaccines Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Product
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cholera Vaccines Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Product
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Cholera Vaccines Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Product
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Cholera Vaccines Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Product
      • 6.3.3.2.3. By Distribution Channel

7. Europe Cholera Vaccines Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Product
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Cholera Vaccines Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Product
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. United Kingdom Cholera Vaccines Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Product
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. Italy Cholera Vaccines Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Product
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. France Cholera Vaccines Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Product
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Cholera Vaccines Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Product
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Cholera Vaccines Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Product
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Cholera Vaccines Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Product
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Cholera Vaccines Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Product
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Cholera Vaccines Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Product
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Cholera Vaccines Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Product
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Cholera Vaccines Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Product
      • 8.3.5.2.3. By Distribution Channel

9. South America Cholera Vaccines Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Product
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Cholera Vaccines Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Product
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Cholera Vaccines Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Product
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Cholera Vaccines Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Product
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Cholera Vaccines Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Product
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Cholera Vaccines Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Product
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Cholera Vaccines Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Product
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Cholera Vaccines Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Product
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Valneva SE
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Sanofi S.A.
• 14.3. Emergent BioSolutions Inc.
• 14.4. EuBiologics Co., Ltd.
• 14.5. Shantha Biotechnics Limited
• 14.6. Hilleman Laboratories Singapore Pte Ltd
• 14.7. Astellas Pharma Inc.
• 14.8. Incepta Pharmaceuticals Ltd.
• 14.9. Bharat Biotech Ltd.
• 14.10. Takeda Pharmaceutical Company Limited

15. Strategic Recommendations

16. About Us & Disclaimer